The Role of Gut Dysbiosis and Potential Approaches to Target the Gut Microbiota in Multiple Sclerosis.
- Published in:
- CNS Drugs, 2023, v. 37, n. 2, p. 117, doi. 10.1007/s40263-023-00986-w
- By:
- Publication type:
- Article
Works matching IS 11727047 AND DT 2023 AND VI 37 AND IP 2
Results: 6
1
2
Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine.
- Published in:
- CNS Drugs, 2023, v. 37, n. 2, p. 189, doi. 10.1007/s40263-022-00983-5
- By:
- Publication type:
- Article
3
Teriflunomide Concentrations in Cerebrospinal Fluid and Plasma in Patients with Multiple Sclerosis: A Pharmacokinetic Study.
- Published in:
- CNS Drugs, 2023, v. 37, n. 2, p. 181, doi. 10.1007/s40263-023-00985-x
- By:
- Publication type:
- Article
4
Ketamine and Zinc: Treatment of Anorexia Nervosa Via Dual NMDA Receptor Modulation.
- Published in:
- CNS Drugs, 2023, v. 37, n. 2, p. 159, doi. 10.1007/s40263-022-00984-4
- By:
- Publication type:
- Article
5
Apixaban for the Treatment of Cerebral Venous Sinus Thrombosis: A Single-Centre Experience and Systematic Review of the Literature.
- Published in:
- CNS Drugs, 2023, v. 37, n. 2, p. 133, doi. 10.1007/s40263-022-00981-7
- By:
- Publication type:
- Article
6
Estimating Risk of Antidepressant Withdrawal from a Review of Published Data.
- Published in:
- CNS Drugs, 2023, v. 37, n. 2, p. 143, doi. 10.1007/s40263-022-00960-y
- By:
- Publication type:
- Article